Project: A unique tolerance inducing therapy for the treatment of the Orphan disease Myasthenia Gravis (MG)
Toleranzia is developing a new and unique therapy for the treatment of the autoimmune Orphan disease Myasthenia Gravis. Taking advantage of the abilities of Cholera toxin to modulate the immune system, a therapeutic fusion protein that promotes induction of tolerance to incorporated disease-specific peptides has been developed. The proof of concept in an animal model will be validated in human cells; the drug substance produced and preparations for preclinical and clinical studies performed.
| Acronym | TolerizeMG (Reference Number: 9480) |
| Duration | 01/04/2015 - 01/05/2016 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 2 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 20804 | Toleranzia AB | Coordinator | Sweden |
| 20805 | UAB “Biotechnologines farmacijos centras „Biotechpharma“ | Partner | Lithuania |
| 20806 | Bioneer | Partner | Denmark |
| 20807 | Klifo A/S | Partner | Denmark |